Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications

Abstract

Thyroid hormone receptors (THRs), a crucial nuclear receptor protein family, primarily consist of two categories: receptors and receptors. Among them, THR is the primary subtype of thyroid hormone that confers benefits to the liver. In the last two decades, there have been efforts to develop THR agonists that selectively yield beneficial effects on the liver, such as lowering triglycerides and cholesterol, while reducing adverse effects on the heart, muscle, and bone. This paper systematically reviews strategies to enhance the safety of THR agonists for the treatment of MASH, with a focus on improving the selectivity of THR and increasing the distribution of the drug in the liver. Additionally, we explore the potential application of this target in addressing other medical indications.